JPRN-UMIN000008953已完成2 期
Phase II Study of De-intensified Treatment (radiation alone) for Human Papilloma Virus-Associated Oropharyngeal Cancer - Radiotherapy for HPV Associated Oropharyngeal Cancer
Osaka University Graduate School of Medicine, Dept. of Otorhinolaryngology-Head and Neck Surgery0 个研究点目标入组 39 人开始时间: 2012年9月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. previously irradiated the same field as currently scheduled 2. presence of active second primary cancer. heterochronic second primary cancers with no evidence of disease more than 36 months and superficial second primary cancers are allowed. 3. presence of active infectious disease or presence of fever above 38 centidegree 4. cases judged as inappropriate 5. T4 or/and N3
研究者
相似试验
进行中（未招募）
2 期
Phase II study of intensive treatment for newly diagnosed elderly acute myeloid leukemia, fitted for standard chemotherapy like younger adults, by Japan Adult Leukemia Study Group (JALSG-GML219)acute myeloid leukemiaJPRN-jRCTs041190088Ito Yoshikazu128
进行中（未招募）
1 期
A Study, in which patients with advanced hepatocellular carcinoma (HCC) and preserved liver function are treated with a reduced starting dose ofcabozantinib, followed by an increase of dose, after treatment failure of one previous therapyAdvanced stage hepatocellular carcinoma (HCC) patients with preserved liver function in second line therapyEUCTR2020-000775-20-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest40
进行中（未招募）
不适用
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive chronic lymphocytic leukemia (CLL), low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantion. - STP-LYM-01-V01EUCTR2009-014641-88-DEMedizinische Fakultaet der Technischen Universitaet Muenchen
进行中（未招募）
不适用
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemiarelapsed or refractory Chronic Lymphocytic LeukemiaMedDRA version: 9.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaEUCTR2006-006694-24-DEFresenius Biotech GmbH
已完成
2 期
Phase II study of remission induction therapy with bendamustine and rituximab combination (BR) therapy followed by consolidation therapy with 90Y-labeled iburitumomab tiuxetan for relapsed follicular lymphoma.(BRiZ2012 protocol)follicular lymphomaJPRN-UMIN000008793Society of Lymphoma Treatment in Japan (SoLTJ)28